Review article: Breath testing for human liver function assessment

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 12, 2002, Pages 1977-1996

  Armuzzi, A ^a,b   Candelli, M ^a   Zocco, M A ^a   Andreoli, A ^b   De Lorenzo, A ^b   Nista, E C ^a   Miele, L ^a   Cremonini, F ^a   Cazzato, I A ^a   Grieco, A ^a   Gasbarrini, G ^a   Gasbarrini, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOISOCAPROIC ACID; 4 ACETANISIDINE; ALLOPURINOL; AMINO ACID; AMINOPHENAZONE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAFFEINE; CARBON 13; CARBON 14; CIMETIDINE; CYTOCHROME P450; DIAZEPAM; DISULFIRAM; DIURETIC AGENT; ERYTHROMYCIN; GALACTOSE; GLUTETHIMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHIONINE; PARACETAMOL; PHENACETIN; PHENOBARBITAL; PHENYLALANINE; PHENYTOIN; SPIRONOLACTONE; STEROID; UNINDEXED DRUG;

ABSTINENCE; ALCOHOL LIVER CIRRHOSIS; AMINO ACID METABOLISM; BREATH ANALYSIS; CHRONIC LIVER DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG METABOLISM; ENZYME ACTIVITY; FOLLOW UP; GENE MUTATION; GRAFT REJECTION; HUMAN; ISOTOPE LABELING; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LIVER METABOLISM; LIVER MICROSOME; LIVER TOXICITY; LIVER TRANSPLANTATION; NUTRITIONAL STATUS; PATIENT MONITORING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SCREENING TEST; SEX DIFFERENCE;

BREATH TESTS; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; MICROSOMES, LIVER; MITOCHONDRIA, LIVER; PROGNOSIS;

EID: 0036913675     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01374.x     Document Type: Review

References (189)

1. Tygstrup N. Assessment of liver function: Principles and practice. J Gastroenterol Hepatol 1990; 5: 468-82.
2. Laker MF. Liver function tests. Br Med J 1990; 301: 250-1.
3. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG. ed. The Liver and Portal Hypertension. Philadelphia: W. B. Saunders. 1964: 50.
4. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
5. Barstow L, Small RE. Liver function assessment by drug metabolism. Pharmacotherapy 1990; 10: 280-8.
6. Brockmöller J, Roots I. Assessment of liver metabolic function. Clin Pharmacokinet 1994; 27: 216-48.
7. Jalan R, Hayes PC. Quantitative tests of liver function. Aliment Pharmacol Ther 1995; 9: 263-70.
8. Bircher J. Quantitative assessment of deranged hepatic function: A missed opportunity? Semin Liver Dis 1983; 3: 275-84.
9. Wheeler HO, Meltzer JI, Bradley SE. Biliary transport and hepatic storage of sulphobromophtalein sodium in the unanaesthetized dog, in normal man and in patients with hepatic diseases. J Clin Invest 1960; 39: 1131-44.
10. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961; 21: 43-57.
11. Tygstrup N. The galactose elimination capacity in control subjects and in patients with cirrhosis of the liver. Acta Med Scand 1964; 175: 281-9.
12. Molino G, Cavanna A, Avagnina P, Ballare M, Torchio M. The hepatic clearance of D-sorbitol: A non-invasive test for evaluating the functional liver plasma flow. Dig Dis Sci 1987; 32: 753-8.
13. Branch RA, Herbert CM. Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973; 14: 569-73.
14. Renner E, Weigholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: A model compound for measuring liver function. Hepatology 1984; 4: 38-46.
15. Vilstrup H. Synthesis of urea after stimulation with amino acid: Relation to liver function. Gut 1980; 21: 990-5.
16. Oellerich M, Burdelsky M, Ringe B, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; i: 640-2.
17. 13C breath tests for measurement of liver function. Gut 1998; 43(Suppl. 3): S25-7.
18. 2 measurements. Fed Proc 1982; 41: 2698-701.
19. 2 breath tests. In: Paust H, Park W, Helge H, et al., eds. Klinische Ernährung. Vol. 34. München: W. Zuckschwerdt Verlag. 1988; 52-61.
20. Schwabe A, Cozzetto F, Bennet L, Mellinkoff S. Estimation of fat absorption by monitoring expired carbon dioxide after feeding a radioactive fat. Gastroenterology 1962; 42: 285-91.
21. 2 breath test: Methodology and fundamental considerations. J Lab Clin Med 1977; 90: 412-21.
22. 14C]-aminopyrine breath test: A comparison of different forms of analysis. Br J Clin Pharmacol 1979; 8: 539-445.
23. Schoeller DA, Baker AL, Monroe PS, Krager PS, Schneider JF. Comparison of different methods of expressing results of the aminopyrine breath test. Hepatology 1982; 2: 455-62.
24. Baker AL, Kotake AN, Schoeller DA. Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis 1983; 3: 318-29.
25. 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 1974; 291: 1384-8.
26. 14C] phenacetin breath test to measure hepatic function in man. Hepatology 1984; 4: 47-52.
27. 13C] methacetin breath test for evaluation of liver damage. Dig Dis Sci 1987; 32: 344-8.
28. 13C) caffeine in man using respiratory exchange measurements. Biomed Mass Spectrom 1980; 7: 521-4.
29. Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: Diazepam breath test and correlation in drug elimination. J Lab Clin Med 1977; 90: 440-56.
30. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989; 83: 688-97.
31. 13C] phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg 1997; 173: 270-4.
32. 2. Gastroenterology 1976; 72: 98-101.
33. Lauterburg BH, Liang D, Schwarzenbach FA, Breen KJ. Mitochondrial dysfunction in alcoholic patients as assessed by breath analysis. Hepatology 1993; 17: 418-22.
34. 13C-methionine breath test. Scand J Gastroenterol 2000; 35: 650-3.
35. 14C]-aminopyrine. Ann Intern Med 1975; 83: 632-8.
36. Reichen J. Assessment of hepatic function with xenobiotics. Semin Liver Dis 1995; 15: 189-201.
37. Perri F, Pastore M, Annese V, Andriulli A. The aminopyrine breath test. Ital J Gastroenterol 1994; 26: 306-17.
38. Irving CS, Schoeller DA, Nakamura KI, Baker AL, Klein PD. The aminopyrine breath test as a measure of liver function. A quantitative description of its metabolic basis in normal subjects. J Lab Clin Med 1982; 100: 356-73.
39. 14C) aminopyrine breath test in liver disease. Gut 1978; 19: 40-5.
40. Narducci F, Morelli A. Usefulness of aminopyrine breath test in chronic hepatitis. IRCS Med Sci 1981; 9: 493.
41. 14C) aminopyrine breath test in chronic liver disease. Dig Dis Sci 1981; 26: 1078-83.
42. Monroe PS, Baker AL, Schneider JF, Krager PS, Klein PD, Schoeller DA. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982; 2: 317-22.
43. Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21: 260-5.
44. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 717-25.
45. Herold C, Berg P, Kupfal D, et al. Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C. Dig Dis Sci 2000; 45: 2233-7.
46. Carlisle R, Galambos JT, Warren DW. The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig Dis Sci 1979; 24: 358-62.
47. 13C-breath test for quantitative assessment of liver function in humans. Hepatogastroenterology 1995; 42: 931-8.
48. Herold C, Heinz R, Raderspiel-Troger M, Schneider HT, Schuppan D, Hahn EG. Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. Liver 2001; 21: 26-30.
49. Villeneuve JP, Infante-Rivard C, Ampelas M, Pomier-Layrargues G, Huet PM, Marleau D. Prognostic value of the aminopyrine breath test in cirrhotic patients. Hepatology 1986; 6: 928-31.
50. Adler M, Van Laethem J, Gilbert A, et al. Factors influencing survival at one year in patients with non biliary hepatic parenchymal cirrhosis. Dig Dis Sci 1990; 35: 1-5.
51. 14C-aminopyrine breath test compared to Child-Pugh score and serum bile acids in 84 cirrhotic patients. Digestion 1991; 50: 212-8.
52. Merkel C, Bolognesi M, Bellon S, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33: 836-42.
53. Merkel C, Morabito A, Sacerdoti D, Bolognesi M, Angeli P, Gatta A. Updating prognosis of cirrhosis by Cox's regression model using Child-Pugh score and aminopyrine breath test as time-dependent covariates. Ital J Gastroenterol Hepatol 1998; 30: 276-82.
54. Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary sodium balance in patients with cirrhosis: Relationship to quantitative parameters of liver function. Hepatology 1997; 26: 1149-55.
55. Saunders JB, Lewis KO, Paton A. Early diagnosis of alcoholic cirrhosis by the aminopyrine breath test. Gastroenterology 1980; 79: 112-4.
56. Morelli A, Narducci F, Pelli MA, Farroni F, Vedovelli A. The relationship between aminopyrine breath test and severity of liver disease in cirrhosis. Am J Gastroenterol 1981; 76: 110-3.
57. 14C] aminopyrine in liver diseases. Dig Dis Sci 1982; 27: 49-56.
58. Schneider JF, Baker AL, Haines NW, Hatfield G, Boyer JL. Aminopyrine N-demethylation: A prognostic test of liver function in patients with alcoholic liver disease. Gostroenterology 1980; 79: 1145-50.
59. Lewis KO, Nicholson G, Lance P, Paton A. Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs. J Clin Pathol 1977; 30: 1040-3.
60. Lotterer E, Hogel J, Gaus W, Fleig WE, Bircher J. Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: A retrospective feasibility study. Hepatology 1997; 26: 1426-33.
61. Herold C, Ganslmayer M, Deynet C, Hahn EG, Schuppan D. Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis. Liver 2002; 22: 159-65.
62. Hepner GW, Vesell ES. Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition. Clin Pharmacol Ther 1977; 21: 620-6.
63. Hepner GW, Uhlin SR, Lipton A, Harvey HA, Rohrer V. Abnormal aminopyrine metabolism in patients with hepatic neoplasms. Detection by breath test. J Am Med Assoc 1976; 236: 1587-90.
64. Gill RA, Goodman MW, Golfus GR, Onstad GR, Bubrick MP. Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg 1983; 198: 701-4.
65. 14C]aminopyrine demethylation capacity after portocaval shunting. Comparative study in patients with and without arterialization of portal vein. Dig Dis Sci 1993; 38: 2177-82.
66. Bollschweiler E, Schroder W, Holscher AH, Siewert JR. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg 2000; 87: 1106-10.
67. 14C]aminopyrine breath test. Transplant Proc 1993; 25: 2640-1.
68. 13C. In: Goldstein S, Louver P, Soulié E, eds. Les Isotopes Stables: Applications-Production. Lyon: CEA Editions, 1993: 239-46.
69. 14C-aminopyrine breath test. Br Med J 1980; 1; 279-80.
70. 13C-aminopyrine breath test. Eur J Pediatr 1982; 139: 129-34.
71. Shulman RJ, Irving CS, Boutton TW, Wong WW, Nichols BL, Klein PD. Effect of infant age on aminopyrine breath test results. Pediatr Res 1985; 19: 441-5.
72. Henderson G, Secor J, Heitman D, Schenker S. Effects of age and sex on the hepatic monoxygenase system: A correlative approach. Dev Pharmacol Ther 1986; 9: 201-16.
73. Schnegg M, Lauterburg BH. Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 1986; 3: 164-71.
74. 14C-aminopyrine, studied by the breath test. Digestion 1983; 28: 210-5.
75. 13C]aminopyrine breath test detects altered liver metabolism caused by low-dose oral contraceptives. Dig Dis Sci 1995; 40: 2417-22.
76. 13C]aminopyrine breath test. Dig Dis Sci 2001; 46: 133-9.
77. Mehta S. Malnutrition and drugs: Clinical implications. Dev Pharmacol Ther 1990; 5: 159-65.
78. Hepner GW, Vesell ES, Tantum KR. Reduced drug elimination in congestive heart failure. Studies using aminopyrine as a model drug. Am J Med 1978; 65: 371-6.
79. Heinrich HG, Mayer WK, Adler D, Hornak H, Wunschmann HJ. Studies of dialysis patients using the 14C aminopyrine breath test. Z Gastroenterol 1989; 49: 76-8.
80. Bircher J, Kuepfer A, Gikalow I, Preisig R. Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 1976; 20: 484-92.
81. Villeneuve JP, Arsene D, Huet PM. Assessment of liver function by the aminopyrine breath test. Clin Invest Med 1983; 6: 5-9.
82. Nelson DC, Avant GR, Speeg KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug metabolism in cirrhotics. Hepatology 1985; 5: 305-9.
83. Barry M, Feely J. Allopurinol influences aminophenazone elimination. Clin Phamacokinet 1990; 47: 347-53.
84. Steiger U, Cotting J, Reichen J. Albendazole treatment of echinococcosis in humans: Effect on microsomial metabolism and drug tolerance. Clin Pharmacol Ther 1990; 47: 347-53.
85. Lipton A, Hepner GW, White D, Harvey H. Decreased hepatic drug demethylation in patients receiving chemo-immunotherapy. Cancer 1978; 41: 1680-4.
86. Horsmans Y, Brenard R, Geubel AP. Short report: Interferon-alpha decreases 14C-aminopyrine breath test values in patients with chronic hepatitis C. Aliment Pharmacol Ther 1994; 8: 353-5.
87. Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305: 1262-4.
88. 14C-aminophenazone breath test in pesticide workers. Int Arch Occup Environ Health 1986; 57: 185-93.
89. Lane EA. The aminopyrine breath test for the evaluation of liver function in alcoholic patients: Drug pharmacokinetics and environmental factors. Adv Alcohol Subst Abuse 1988; 7: 25-32.
90. Boersma JW. Preventie van agranulocytose tijdens het gebruik van pyrazolonederivaten, in her bijzonder van aminofenazone. Ned Tijdschr Geneskd 1973; 117: 376-83.
91. 2 breath analysis as measurement of demethylation of stable isotope labelled aminopyrine in man. Clin Chim Acta 1978; 84: 153-62.
92. PA (P4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-700.
93. Raaflaub J, Dubach UC. On the pharmacokinetics of phenacetin in man. Eur J Clin Pharmacol 1975; 8: 261-5.
94. Schoeller DA, Kotake AN, Lambert GH, Krager PS, Baker AL. Comparison of the phenacetin and aminopyrine breath test: Effect of liver disease, inducers and cobaltus chloride. Hepatology 1985; 5: 276-81.
95. 13C-phenacetin metabolism. II. A combination of breath test and urine test of in vivo metabolites in the diagnosis of liver disease. Chem Pharm Bull (Tokyo) 1996; 44: 1258-60.
96. Pantuck EJ, Kuntzman R, Conney AH. Decreased concentration of phenacetin in plasma of cigarette smokers. Science 1972; 175: 1248-50.
97. 13C-methacetin for the detection of alterations in hepatic drug metabolism. In: Klein ER, Klein PD, eds. Stable Isotopes: Proceedings of the Third International Conference. New York: Academic Press. 1979; 507-16.
98. 13C-methacetin. Eur J Nucl Med 1985; 10: 129-33.
99. 2-methacetin breath test (MBT) for hepatic function. A noninvasive approach. Hepatology 1984; 4: 1094.
100. 2-methacetin breath test (MBT): A comparative analysis. Hepatology 1984; 4: 1094.
101. 13C-methacetin breath test for quantitative liver function testing. Z Gastroenterol 1997; 35: 609-14.
102. 13C-methacetin breath test for quantitative noninvasive liver function analysis with an isotope-specific nondispersive infrared spectrometer in liver cirrhosis. Dtsch Med Wochenschr 1998; 123: 1467-71.
103. 13C-methacetin breath test: Isotope-selective nondispersive infrared spectrometry in comparison to isotope ratio mass spectrometry in volunteers and in patients with liver cirrhosis. Z Gastroenterol 1999; 37: 1139-43.
104. 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Digest Liver Dis 2000; 32: 226-32.
105. Tanaka E, Breimer DD. In vivo function test of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 1997; 22: 237-49.
106. Wietholtz H, Voegelin M, Arnaud MJ, Bircher J, Preisig R. Assessment of the cytochrome P-448 dependent liver enzyme system by a caffeine breath test. Eur J Clin Pharmacol 1981; 21: 53-9.
107. 2 breath test: Dose-response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32: 261-9.
108. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: A model compound for measuring liver function. Hepatology 1984; 4: 38-46.
109. 14C-caffeine breath test. Pharmacol Toxicol 1995; 77: 247-9.
110. Juan D, Worwag EM, Schoeller DA, Kotake AN, Hughes RL, Frederiksen MC. Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. Clin Pharmacol Ther 1986; 40: 187-94.
111. Lambert GH, Schoeller DA, Humphrey HE, et al. The caffeine breath test and caffeine urinary metabolize ratios in the Michigan cohort exposed to polybrominated biphenyls: A preliminary study. Environ Health Perspect 1990; 89: 175-91.
112. Juan D, Molitch ME, Johnson MK, Carlson RF, Antal EJ. Unaltered drug metabolizing enzyme system in type II diabetes mellitus before and during glyburide therapy. J Clin Pharmacol 1990; 30: 943-7.
113. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170-80.
114. Rost KL, Brosicke H, Heinemeyer G, Roots I. Specific and dose-dependent induction by omeprazole in human beings. Hepatology 1994; 20: 1204-12.
115. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-11.
116. Andersson T, Holmberg J, Rohss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369-75.
117. Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine toxicity. Hepatology 1996; 23: 1429-35.
118. 2 breath test. Pediatr Res 1988; 23: 632-6.
119. 2 breath test. Dev Pharmacol Ther 1989; 12: 90-5.
120. Parker AC, Preston T, Heaf D, Kitteringham NR, Choonara I. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br J Clin Pharmacol 1994; 38: 573-6.
121. Parker AC, Pritchard P, Preston T, Smyth RL, Choonara I. Enhanced drug metabolism in young children with cystic fibrosis. Arch Dis Child 1997; 77: 239-41.
122. Parker AC, Pritchard P, Preston T, Dalzell AM, Choonara I. Lack of inhibitory effect of cimetidine on caffeine metabolism in children using the caffeine breath test. Br J Clin Pharmacol 1997; 43: 467-70.
123. Parker AC, Pritchard P, Preston T, Choonara I. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998; 45: 176-8.
124. Sonnenberg A, Koelz HR, Herz R, Benes I, Blum AL. Limited usefulness of the breath test in evaluation of drug metabolism: A study in human oral contraceptive users treated with dimethylaminoantipyrine and diazepam. Hepatogastroenterology 1980; 27: 104-8.
125. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver mlcrosomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.
126. Pinta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23.
127. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-84.
128. Lown K, Kolars JC, Turgeon K, Merion RM, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992; 51: 229-38.
129. Chiou WL, Jeong HY, Wu TC, Ma C. Use of erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther 2001; 70: 305-10.
130. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990; 48: 120-9.
131. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990; 335: 11-5.
132. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20: 309-16.
133. Schmidt LE, Kristensen Olsen A, Stentoft K, Rasmussen A, Kirkegaard P, Dalhoff K. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients. Clin Pharmacol Ther 2001; 70: 446-54.
134. Craig PI, Tapner M, Farrel GC. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology 1993; 17: 230-5.
135. Hirth JA, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6: 1255-8.
136. Watkins PB. Erythromycin breath test and clinical transplantation. Ther Drug Monit 1996; 18: 368-71.
137. Rivory LP, Slaviero K, Seale JP, et al. Optimizing the erythromycin breath test for use in cancer patients. Clin Cancer Res 2000; 6: 3480-5.
138. Kolars JC, Schmeeidlin-Ren P, Scheutz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450 IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1971-8.
139. Cuatrecasas P, Segal S. Mammalian galactokinase: Development and adaptive characteristics in the rat liver. J Biol Chem 1965; 240: 2382-8.
140. Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: The effect of liver disease. Gastroenterology 1982; 83: 1090-6.
141. Tengstrom B. The discriminatory ability of a galactose tolerance test and some other tests in the diagnosis of cirrhosis of the liver, hepatitis, and biliary obstruction. Scand J Clin Lab Med 1969; 23: 159-68.
142. Marchesini G, Fabbri A, Bugianesi E, et al. Analysis of the deterioration rates of liver function in cirrhosis, based on galactose elimination capacity. Liver 1990; 10: 65-71.
143. Reichen J, Widmer T, Cotting J. Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: A comparison with the Mayo model. Hepatology 1991; 14: 504-10.
144. Salerno F, Borroni G, Moser P, et al. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. J Hepatol 1996; 25: 474-80.
145. Merkel C, Marchesini G, Fabbri A, et al. The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death. Hepatology 1996; 24: 820-3.
146. 14C-D-galactose breath test for evaluation of liver function in patients with chronic liver disease. Digestion 1978; 17: 410-8.
147. Grimm L, Bircher J, Preisig R. Der galaktose-atemtest. Modification der methodik und vergleich mit der galaktose-eliminationskapazität und dem verschwinden von bromsulphthalein. Z Gastroenterol 1980; 18: 45-56.
148. 13C galactose breath tests: A sensitive test to measure liver function. Gut 1998; 43(Suppl. 3): S25-6.
149. 13C]-galactose breath test: Correlation with liver fibrosis in chronic hepatitis C. Eur J Clin Invest 1999; 29: 624-9.
150. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
151. 13C)tyrosine in the postabsorptive state. Metabolism 1982; 31: 999-1005.
152. Iber FL, Rosen H, Levenson SM, Chalmers TC. The plasma amino acids in patients with liver failure. J Lab Clin Med 1967; 50: 417-25.
153. Levine TJ, Conn HO. Tyrosine metabolism in patients with liver disease. J Clin Invest 1967; 46: 2012-20.
154. O'Keefe SJD, Abraham R, El-Zayadi A, Marshall W, Davis M, Williams R. Increased plasma tyrosine concentrations in patients with cirrhosis and fulminant hepatic failure associated with increased plasma tyrosine flux and reduced hepatic oxidation capacity. Gastroenterology 1981; 81: 1017-24.
155. Hehir DJ, Jenkins RL, Bistrian BR, et al. Abnormal phenylalanine hydroxylation and tyrosine oxidation in a patient with acute fulminant liver disease with correction by liver transplantation. Gastroenterology 1985; 89: 659-63.
156. Heberer M, Talke H, Maier KP, Gerok W. Metabolism of phenylalanine in liver disease. Klin Wochenschr 1980; 58: 1189-96.
157. 13C-phenylalanine breath test. Chem Pharm Bull (Tokyo) 1998; 46: 1330-2.
158. 13C-tyrosine breath tests for the measurement of hepatocyte functional capacity in patients with liver cirrhosis. Chem Pharm Bull (Tokyo) 2001; 49: 1507-11.
159. 2 ratio by IRMS and NDIRS. Isotopes Environ Health Stud 1998; 34: 209-13.
160. 13C]phenylalanine breath test. Eur J Clin Invest 2001; 31: 356-61.
161. 13C]phenylalanine breath test for the assessment of liver function. Isotopes Environ Health Stud 1999; 35: 147-56.
162. Krahenbuhl S. Alterations in mitochondrial function and morphology in chronic liver disease: Pathogenesis and potential for therapeutic intervention. Pharmacol Ther 1993; 60: 1-38.
163. Fromenty B, Pessayre D. Inhibition of mitochondriai beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67: 101-54.
164. Ozawa K, Aoyama H, Yasuda K, et al. Metabolic abnormalities associated with postoperative organ failure. A redox theory. Arch Surg 1983; 118: 1245-51.
165. Ahem DA, Mitchell ME. Liver function in protein-energy malnutrition measured by cinnamic acid tolerance and benzoic acid tolerance: Effect of carnitine supplementation. Br J Nutr 1989; 61: 209-21.
166. Bianchi G, Marchesini G, Vilstrup H, et al. Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method. Hepatology 1991; 13: 460-6.
167. 31Phosphorus spectroscopy. Hepatology 1992; 15: 835-42.
168. Harper AE, Miller RH, Block KP. Branched-chain amino acids metabolism. Annu Rev Nutr 1984; 4: 409-54.
169. Khatra BS, Chawla RK, Sewell CW, Rudman D. Distribution of branched-chain α-keto acid dehydrogenases in primate tissues. J Clin Invest 1977; 59: 558-64.
170. 13C]ketoisocaproate is impaired in alcoholics. Alcohol Clin Exp Res 1994; 18: 951-5.
171. Mion F, Rousseau M, Brazier JL, Minaire Y. Human hepatic macrovesicular steatosis: A noninvasive study of mitochondrial ketoisocaproic acid decarboxylation. Metabolism 1995; 44: 699-700.
172. Bendtsen P, Hannestad U, Pahllson P. Evaluation of the carbon 13-labeled ketoisocaproate breath test to assess mitochondrial dysfunction in patients with high alcohol consumption. Alcohol Clin Exp Res 1998; 22: 1792-5.
173. Yeaman SJ. The mammalian 2-oxoacid dehydrogenases: A complex family. Trends Biol Sci 1986; 11: 293-6.
174. Lauterburg BH, Grattagliano I, Gmur R, Stalder M, Hildebrand P. Noninvasive assessment of the effect of xenobiotics on mitochondrial function in human beings: Studies with acetylsalicylic acid and ethanol with the use of the carbon 13-labeled ketoisocaproate breath test. J Lab Clin Med 1995; 125: 378-83.
175. Lieber CS. Ethanol metabolism, cirrhosis and alcoholism. Clin Chim Acta 1997; 257: 59-84.
176. Brody TM. Action of sodium salicylate and related compounds on tissue metabolism in vitro. J Pharmacol Exp Ther 1956; 117: 39-51.
177. Honkoop P, De Man RA, Scholte HR, et al. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 1997; 26: 211-5.
178. Gabe SM, Bjarnason I, Tolou-Ghamari Z, et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998; 115: 67-74.
179. Harper AE. Amino acid metabolism in clinical medicine: Some recent developments in the study of amino acids metabolism. Proc Nutr Soc 1983; 42: 437-49.
180. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: Molecular mechanisms and clinical implications. Pharmacol Ther 1997; 73: 265-80.
181. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-36.
182. Stipanuk MH. Metabolism of sulfur-containing amino acids. Ann Rev Nutr 1986; 6: 179-209.
183. Giulidori P, Galli-Kienle M, Catto E, Stramentinoli G. Transmethylation, transsulfuration, and aminopropylation reactions of S-adenosyl-L-methionine in vivo. J Biol Chem 1984; 259: 4205-11.
184. Mudd SH, Poole JR. Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975; 24: 721-35.
185. 13C]methionine breath test be useful to assess liver mitochondrial function? Dig Dis Sci 2001; 46: 2758-61.
186. Woolf GM, Wagner DA, Cohen SM, Vierling JM. A breath test to determine hepatic mitochondrial function. Hepatology 1997; 26 (No 4. Part 2): 271A.
187. Spahr L, Negro F, Martha J, Hadengue A. Non-invasive evaluation of liver mitochondrial function by methionine breath test. Hepatology 1999; 30 (No 4. Part 2): 321A.
188. Bircher J. Assessment of prognosis in advanced liver disease: To score or to measure, that's the question. Hepatology 1986; 6: 1036-7.
189. 13C-breath tests: Vision and realities. J Nutr 2001; 131: 1637S-42S.